Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aspen Faces Vaccine Setback In South Africa As Strides Explores Oral COVID Treatment

Dr Reddy’s, Lupin, Cipla And Sun Pharma Partner With Eli Lilly For Baricitinib In India

Executive Summary

After a production setback, Aspen and Johnson & Johnson announce a donation of 300,000 vaccines to South African teachers. Strides partners with Ennaid for an oral COVID drug, while Dr Reddy’s, Lupin, Cipla and Sun Pharma Partner with Eli Lilly for baricitinib in India and Formycon receives approval for early action for its COVID-19 drug.

You may also be interested in...



Strides Fights COVID-19-Led Sales Slump With Endo Assets, Sputnik V

After a COVID-19-led manufacturing halt at its India facility and a slowdown in US launches hit Strides during the first quarter of FY22, the Indian firm is trying to fight back with an acquisition of assets from Endo and a growth strategy for Stelis Biopharma’s vaccines business, led by Sputnik V.

Alvogen Companies Donate To Support COVID Vaccines

Alvogen and sister company Alvotech have donated to UNICEF to support vaccine supply to over 90 low-and-middle-income countries, while Hikma has also made a multi-million-dollar donation. India’s Dr Reddy’s is moving ahead with the Sputnik V vaccine, while AstraZeneca is partnering with Insud Pharma on its vaccine in Spain. Meanwhile, the UK government has extended its vaccination contract with Wockhardt.

Bill & Melinda Gates Foundation Commits $120m For Molnupiravir In Lower-Income Countries

The Bill & Melinda Gates Foundation has extended a financial commitment of up to $120m to secure a dedicated, low-cost supply of generic molnupiravir to lower-income countries. The Gates Foundation is looking to “significantly reduce the time it takes for a new drug to reach low-income countries after it becomes available in high-income markets.”

Topics

Related Companies

UsernamePublicRestriction

Register

GB151024

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel